JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer
Collaboration leverages JURA Bio’s T cell receptor (TCR) discovery platform to discover and develop innovative therapies by applying…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
22 Sep 23
Collaboration leverages JURA Bio’s T cell receptor (TCR) discovery platform to discover and develop innovative therapies by applying…
21 Sep 23
Everest will obtain exclusive rights to develop and commercialise zetomipzomib in Greater China, South Korea, and other South…
21 Sep 23
Under the licensing agreement, RefleXion will develop and commercialise RXM-4768 molecule to direct its SCINTIX biology-guided radiotherapy
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Sep 23
Under the partnership, both parties will discover novel small molecule drugs using Orionis’s Allo-Glue platform for challenging targets…
21 Sep 23
The agreement grants Kyverna Therapeutics access to Oxford Biomedica's LentiVector platform for use with any Kyverna product
21 Sep 23
The collaboration, which began in March 2020, leverages AbCellera’s antibody discovery engine and Regeneron’s VelocImmune mice to identify…
20 Sep 23
Litfulo works by irreversibly and selectively inhibiting JAK3 and the TEC family of kinases by blocking γ-common cytokine…
20 Sep 23
The primary aim of these collaborations is to advance Merck's research endeavours and generate a range of innovative…
20 Sep 23
Under the agreement, PeptiDream will leverage its PDPS technology to discover, optimise, and develop macrocyclic peptide candidates for…
19 Sep 23
CEPI will contribute up to $90m funding for the partnership, which will support the development of mRNA-based vaccine…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates